The 21st JFCR-ISCC

December 14 (Wed)- 15 (Thu), 2016
Miraikan (National Museum of Emerging Science and Innovation)
2-3-6, Aomi, Koto-ku, Tokyo, Japan

The 21st JFCR-International Symposium on Cancer Chemotherapy (JFCR-ISCC) is scheduled as indicated above.
The JFCR-ISCC aims at information exchange on the latest findings of newly developing molecular-targeted anti-cancer drugs and the related topics. Molecular-targeted anti-cancer drugs have been developing prominently with global standards. Meanwhile, already launched molecular-targeted drugs have often been faced with rather quickly acquired resistance, and various challenges against the resistance are rapidly evolving. Accessing to these information is indispensable, moreover, informal exchanges of personal, very specific, or even unsuccessful experiences, are critically valuable for effective achievements of future drug development. I, as the Chairman of the JFCR-ISCC, believe the Symposium with relatively small size will provide you an excellent opportunity for such communication through personal contacts.
In the upcoming 21st JFCR-ISCC, immuno-oncology, epigenetics, and protein knockdown are the focused topics. I hope the Symposium would be an excellent occasion for you to access the domestic and international developments of novel anti-cancer drugs and also to meet scientists, clinicians, and drug developers. So, I sincerely welcome your participation in the Symposium.

Looking forward to seeing you in Tokyo,

Naoya Fujita, Ph.D.
Chairman, JFCR-ISCC
Center Director, Cancer Chemotherapy Center, JFCR

The 21st Symposium Program Committee

Naoya Fujita(Program Committee Chairman, Cancer Chemotherapy Center, JFCR)

Nobuaki Adachi(Daiichi Sankyo Co., Ltd.)
Shiro Akinaga(Kyowa Hakko Kirin Co., Ltd.)
Shingo Dan(Cancer Chemotherapy Center, JFCR)
Shinji Hagiwara(FUJIFILM Co.)
Kiyohiko Hatake(Cancer Chemotherapy Center, JFCR)
Nobuya Ishii(Chugai Pharmaceutical Co., Ltd.)
Seiji Ito(Bristol-Myers Squibb K.K.)
Masao Iwata(Eisai Co., Ltd)
Tamio Mizukami(Nagahama Institute of Bio-Science and Technology)
Hiroyoshi Nishikawa(National Cancer Center)
Toshiyuki Nomura(Takeda Pharmaceutical Company Ltd.)
Atsushi Ohtsu(National Cancer Center)
Isamu Okamoto(Kyushu University)
Hiroyuki Seimiya(Cancer Chemotherapy Center, JFCR)
Kenji Suzuki(Taiho Pharmaceutical Co., Ltd.)
Kazuhito Yamamoto(Aichi Cancer Center Hospital)
Seiji Yano(Kanazawa University)

December 14

11:00-13:00

Poster mounting

12:00-12:30

Committee meeting

Opening Remark

13:00-13:10

Naoya Fujita (Cancer Chemotherapy Center, JFCR, Tokyo)

Opening remark

I Recent progress in immuno-oncology

Chairpersons: Nils Lonberg (Bristol-Myers Squibb, Redwood City, USA)
Hiroyoshi Nishikawa (National Cancer Center, Kashiwa)

13:10-13:50

Michael Axelson (Bristol-Myers Squibb, Tokyo)

Challenges in the development of immuno-oncology agents and combinations

13:50-14:30

Lillian L. Siu (Princess Margaret Cancer Centre, Toronto, Canada)

Immune co-stimulatory molecules alone or in combination with immune checkpoint inhibitors in clinical trials

14:30-14:40

Discussion

14:40-15:00

Coffee break

II Recent developments of engineered antibodies

Chairpersons: Lillian L. Siu (Princess Margaret Cancer Centre, Toronto, Canada)
Kiyohiko Hatake (Cancer Chemotherapy Center, JFCR, Tokyo)

15:00-15:40

Nils Lonberg (Bristol-Myers Squibb, Redwood City, USA)

Antibody based cancer immunotherapeutics

15:40-16:05

Takahiro Ishiguro (Chugai Pharmaceutical Co., Ltd., Tokyo)

T cell redirecting bispecific antibody targeting Glypican3 : Next approach to cancer immunotherapy

16:05-16:15

Discussion

Poster Session

16:15-17:15

Akihiro Ohashi (Takeda Pharmaceutical Company Limited, Fujisawa)

A novel CDC7-selective inhibitor TAK-931 with potent antitumor activity

Noritaka Tanaka (Cancer Chemotherapy Center, JFCR, Tokyo)

Potential predictive biomarker for sensitivity to tankyrase inhibitors

Sonoko Atsumi (Institute of Microbial Chemistry, Tokyo)

Ertredin, a new inhibitor of sphere & tumor growth, regulates mitochondria & glycolysis in EGFRvIII-transformed cells

Makoto Muroi (RIKEN, Wako)

Analysis of MTH1 inhibitors by ChemProteoBase, the drug-target analysis system based on proteomic profiling

Yoshimi Maekawa (Kyowa Hakko Kirin Co., Ltd., Sunto)

A non-fucosylated fully human monoclonal antibody against IL-3Rα, KHK2823, shows promising pharmacological characteristics in non-clinical studies

Takayoshi Tanaka (Chugai Pharmaceutical Co., Ltd., Tokyo)

Combining tumor glypican-3 expression and CD16 Expression on NK cells from peripheral blood to identify patients responding to codrituzumab/GC33/RO5137382

Yasutoshi Kuboki (National Cancer Center Hospital East, Kashiwa)

Immune and molecular profiling in gastric cancer

Yuji Mishima (Cancer Chemotherapy Center, JFCR, Tokyo)

Clonal heterogeneity and propensity for bone marrow metastasis of multiple myeloma

Hayato Ogura (FUJIFILM Corporation, Ashigarakami)

Development of a novel irreversible FLT3 inhibitor FF-10101 that overcomes drug-resistant FLT3 mutations

Ken Uchibori (Cancer Chemotherapy Center, JFCR, Tokyo)

Identification of inhibitor which can overcome acquired resistance to C797S mediated osimertinib resistance

Cuifang Li (Ono Pharmaceutical Co., Ltd., Mishima)

Characterization of ONO-9330547: A novel and selective Axl/Mer inhibitor

Suguru Ueno (Daiichi Sankyo Co., Ltd., Tokyo)

U3-1402a, a novel HER3-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a potent anti-tumor efficacy

17:15-18:45

Mixer

December 15

III Targeting DNA repair, checkpoint and epigenetic regulators

Chairpersons: Minoru Yoshida (RIKEN, Wako)
Atsushi Ohtsu (National Cancer Center Hospital East, Kashiwa)

9:00-9:40

Yves G. Pommier (National Cancer Institute, NIH, Bethesda, USA)

DNA repair genomic alterations and impact for precision medicine

9:40-10:05

Makoto Nakanishi (The University of Tokyo, Tokyo)

Cancer-specific chemosensitizers targeting G2/M checkpoint

10:05-10:30

Issay Kitabayashi (National Cancer Center, Tokyo)

Novel leukemia stem cell-targeted therapy for acute myeloid leukemia based on dual inhibition of EZH1/EZH2

10:30-10:40

Discussion

10:40-11:00

Coffee break

Poster Discussion Session

Chairperson: Manabu Kawada (Institute of Microbial Chemistry, Tokyo)

11:00-12:00

Mentor: 1: Yves G. Pommier

Poster #: P1-P4

Mentor: 2: Lillian L. Siu

Poster #: P5-P8

Mentor: 3: Sai-Hong Ignatius Ou

Poster #: P9-P12

Luncheon Seminar

Chairperson: Tetsuro Takamatsu (Kyoto Prefectural University of Medicine, Kyoto)

12:10-13:10

Yasutoshi Murayama (Kyoto Prefectural University of Medicine, Kyoto)

Photodynamic diagnosis and therapy of gastro intestinal cancers using 5-aminolevulinic acid

Hideo Fukuhara (Kochi Medical School, Nangoku)

Photodynamic diagnosis of bladder and prostate cancers using 5-aminolevulinic acid

13:00-15:00

Poster removal

Special Lecture

Chairperson: Mitsuaki Yoshida (Cancer Chemotherapy Center, JFCR, Tokyo)

13:20-14:20

Hiroyuki Mano (The University of Tokyo, Tokyo)

Targeting oncogenic fusion genes in cancer therapy

14:20-14:40

Coffee break

IV Protein knockdown as a novel antitumor strategy

Chairpersons: Yves G. Pommier (National Cancer Institute, NIH, Bethesda, USA)
Shiro Akinaga (Kyowa Hakko Kirin Co., Ltd., Sunto)

14:40-15:20

Craig M. Crews (Yale University, New Haven, USA)

PROTACs: inducing protein degradation as a therapeutic strategy

15:20-15:45

Mikihiko Naito (National Institute of Health Sciences, Tokyo)

In vivo protein knockdown by SNIPER recruiting IAP ubiquitin ligases

15:45-16:10

Shuichi Ohkubo (Taiho Pharmaceutical Co., Ltd., Tokyo)

Targeting Cullin-RING ubiquitin ligases by a highly potent NEDD8-activating enzyme inhibitor, TAS4464

16:10-16:20

Discussion

VNew targets and drugs under clinical or preclinical investigations

Chairpersons: Makoto Nishio (Cancer Institute Hospital, JFCR, Tokyo)
Hiroyuki Seimiya (Cancer Chemotherapy Center, JFCR, Tokyo)

16:20-17:00

Sai-Hong Ignatius Ou (University of California, Orange, USA)

Current status and future prospects of personalized medicine of lung cancer

17:00-17:25

Toshio Yoshizawa (Ono Pharmaceutical Co., Ltd., Mishima)

Selective BTK inhibitor ONO-4059 with potent anti-tumor activity in B-cell malignancies

17:25-17:35

Discussion

Closing Remark

17:35-17:50

Yves G. Pommier (National Cancer Institute, NIH, Bethesda, USA)

Closing remark

Page TOP